IntroSpect Digital Therapeutics

IntroSpect Digital Therapeutics is a private digital therapeutics company focused on mental health and precision psychiatry. Launched by atai Life Sciences in 2020, the company develops app- and device-based tools intended to support psychedelic-assisted psychotherapy and other mental health interventions in a more scalable and personalized way. Its approach centers on digital biomarkers, remote patient monitoring, therapeutic content delivery, and modular software that can be paired with drug-based treatments. Publicly described work includes a usability study of its digital therapeutic app alongside standard-of-care ketamine therapy for patients with treatment-resistant depression. The company appears to operate as an early-stage platform business rather than a traditional drug developer with a broad disclosed therapeutic pipeline.